On May 29, 2024 Grey Wolf Therapeutics, a clinical-stage biotechnology company leveraging first-of-its-kind antigen modulation therapies to address the source of immune dysfunction in oncology and autoimmunity, reported that the first clinical data for the company’s lead immuno-oncology candidate, GRWD5769, will be presented at the 2024 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting (Press release, Grey Wolf Therapeutics, MAY 29, 2024, View Source [SID1234643786]). The presented findings will consist of initial data from the company’s ongoing Phase 1/2 clinical trial of the first-in-class ERAP1 inhibitor in a range of solid tumour types. The 2024 ASCO (Free ASCO Whitepaper) Annual Meeting is being held May 31 – June 4, 2024, in Chicago, IL.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the company’s presentation at the 2024 ASCO (Free ASCO Whitepaper) Annual Meeting are as follows:
Abstract Number: 2589
Title: EMITT-1: Proof-of-mechanism immunopeptidome (ImPD) effects at target PK exposure, in a Phase 1 study of GRWD5769 (a first-in-class inhibitor of Endoplasmic Reticulum Aminopeptidase 1 [ERAP1]) in patients with solid malignancies
Presenting Author: Thomas Lillie, M.D., Ph.D., Chief Medical Officer of Grey Wolf Therapeutics
Poster Session: Development Therapeutics – Immunotherapy
Date/Time: Saturday, June 1, 2024, 9:00 a.m. Central Time
Location: Poster Hall – Hall A
Grey Wolf has developed and is advancing a unique immune-oncology therapeutic strategy utilizing a proprietary antigen modulation strategy to reveal novel and potent cancer antigens on the surface of tumour cells. This is achieved through oral delivery of a targeted inhibitor of the endoplasmic reticulum aminopeptidases (ERAP1 or ERAP2), key proteins in the antigen presentation pathway. The targeted inhibition of ERAP is designed to elicit a de novo T cell response against tumours and to avoid T-cell exhaustion, thereby overcoming two key resistance mechanisms to current immuno-oncology therapy. The company is conducting an ongoing adaptive Phase 1/2 clinical trial of GRWD5769, which is evaluating the safety, tolerability, and efficacy of GRWD5769, including a planned combination with the PD-1 inhibitor Libtayo (cemiplimab), in a range of solid tumour types.
The company recently reported that it is expanding the scope of the Phase 1/2 trial, allowing for the enrolment of patients with additional tumour types. Additionally, the company has also recently initiated dosing in the study’s first combination treatment cohort.